Docetaxel Injection, Solution
Product Images NDC 72078-040

12 FDA label images from Mylan Institutional Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 72078-040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Image 1)

Chemical Structure (Image 1)
Chemical structure of Docetaxel (DOCETAXEL ANHYDROUS), shown as a detailed molecular diagram with atoms and bonds illustrating the compound's complex chemical composition.*
FDA Label Image

Figure 9 (Image 10)

Figure 9 (Image 10)
A survival probability curve chart showing survival probability (%) on the y-axis and survival time in months on the x-axis. Two legend groups are plotted: TPF and PF, illustrating comparative survival outcomes over approximately 72 months.*
FDA Label Image

Figure 10 (Image 11)

Figure 10 (Image 11)
A survival probability curve chart comparing two groups labeled TPF and PF over a survival time period of 0 to 72 months. The Y-axis represents survival probability as a percentage from 0 to 100%, and the X-axis indicates survival time in months. Patient numbers at risk are listed below the chart for both groups at various time points.*
FDA Label Image

Carton Novaplus (Image 12)

Carton Novaplus (Image 12)
Packaging label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) intravenous injection solution by Mylan Institutional LLC. The label indicates a multiple-dose vial, ready to add to infusion solution, with warnings for cytotoxic agent handling. Manufactured in India, branded with Novaplus trademark, and includes storage and usage instructions.*
FDA Label Image

Figure 1 (Image 2)

Figure 1 (Image 2)
A survival curve chart showing Disease-Free Survival (DFS) Probability (%) over time in months. It compares two treatment groups labeled TAC and FAC, plotting DFS Probability on the vertical axis against Disease-Free Survival Time on the horizontal axis, ranging from 0 to about 66 months.*
FDA Label Image

Figure 2 (Image 3)

Figure 2 (Image 3)
A survival probability curve graph comparing two treatment groups labeled TAC and FAC over a survival time of 0 to 66 months. The vertical axis shows survival probability as a percentage from 0 to 100%, and the horizontal axis shows survival time in months. The curve for TAC consistently shows higher survival probability than the FAC curve across the timeframe.*
FDA Label Image

Figure 3 (Image 4)

Figure 3 (Image 4)
A Kaplan-Meier survival curve comparing overall survival probabilities over time in months between two groups labeled T75 (solid line) and BSC (dashed line). The graph shows cumulative survival probability on the vertical axis and survival time in months on the horizontal axis, with a noted log-rank p-value of 0.010.*
FDA Label Image

Figure 4 (Image 5)

Figure 4 (Image 5)
A Kaplan-Meier survival curve graph showing cumulative probability over survival time in months. The graph compares overall survival for groups labeled T75 and VI, with curves depicting probability trends over approximately 21 months. A log-rank p-value of 0.13 is indicated, reflecting statistical comparison of the two survival curves.*
FDA Label Image

Figure 5 (Image 6)

Figure 5 (Image 6)
A survival probability curve chart showing survival time in months on the x-axis and survival probability on the y-axis. The graph compares two groups labeled 'T75 q3w' and 'M q3w' with solid and dotted lines representing each group's survival probabilities over a 30-month period.*
FDA Label Image

Figure 6 (Image 7)

Figure 6 (Image 7)
A Kaplan-Meier survival curve graph showing probability (%) on the vertical axis against time in months on the horizontal axis. Two treatment groups are depicted: TCF with a solid line and CF with a dashed line, illustrating their survival probabilities over a period of 24 months.*
FDA Label Image

Figure 7 (Image 8)

Figure 7 (Image 8)
A survival probability curve chart displaying survival time in months on the x-axis and survival probability percentage on the y-axis. Two lines labeled TCF and CF show comparative survival trends over 36 months.*
FDA Label Image

Figure 8 (Image 9)

Figure 8 (Image 9)
A Kaplan-Meier survival curve graph depicting Progression Free Survival (PFS) Probability over time in months. The x-axis represents Progression Free Survival Time ranging from 0 to 42 months, and the y-axis shows PFS Probability as a percentage from 0 to 100%. Two treatment groups are compared: TPF (solid line) and PF (dashed line), with TPF showing higher PFS probabilities over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.